Paper40316348
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.
Price T and 19 others. BMJ Open, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours. Papers, record 40316348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40316348
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Neoplasms | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Lung Neoplasms | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Aged | |
| Adult | |
| Aged, 80 and over | |
| Dose-Response Relationship, Drug |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03853109 | AMG 404 in Patients With Advanced Solid Tumors | Background | Yes |
Source ClinicalTrials.gov
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20935021 | A modified toxicity probability interval method for dose-finding trials. | Clin Trials | 2010 | https://conductscience.org/library/papers/20935021 | PubMed |
| 2 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 3 | 26952546 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. | Lancet | 2016 | https://conductscience.org/library/papers/26952546 | PubMed |
| 4 | 26028255 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26028255 | PubMed |
| 5 | 27928714 | Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. | Invest New Drugs | 2017 | https://conductscience.org/library/papers/27928714 | PubMed |
| 6 | 36587500 | Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. | Int Immunopharmacol | 2023 | https://conductscience.org/library/papers/36587500 | PubMed |
| 7 | 28916617 | Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28916617 | PubMed |
| 8 | 30139382 | Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. | Mol Cancer | 2018 | https://conductscience.org/library/papers/30139382 | PubMed |
| 9 | 35778636 | The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. | Gastric Cancer | 2022 | https://conductscience.org/library/papers/35778636 | PubMed |
| 10 | 28734759 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28734759 | PubMed |
| 11 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 12 | 35228677 | Biomarkers of response to PD-1 pathway blockade. | Br J Cancer | 2022 | https://conductscience.org/library/papers/35228677 | PubMed |
| 13 | 27117531 | Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. | Ann Oncol | 2016 | https://conductscience.org/library/papers/27117531 | PubMed |
| 14 | 33580222 | PD-L1 as a biomarker of response to immune-checkpoint inhibitors. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/33580222 | PubMed |
| 15 | 33264544 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/33264544 | PubMed |
| 16 | 23470321 | Molecular mechanisms of T cell co-stimulation and co-inhibition. | Nat Rev Immunol | 2013 | https://conductscience.org/library/papers/23470321 | PubMed |
| 17 | 32919526 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32919526 | PubMed |
| 18 | 19620385 | Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. | J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19620385 | PubMed |
| 19 | 19095437 | Individual patient data analysis to assess modifications to the RECIST criteria. | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19095437 | PubMed |
| 20 | 32917410 | PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. | Gynecol Oncol | 2020 | https://conductscience.org/library/papers/32917410 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40316348
GET https://conductscience.org/api/papers/v1/40316348/references?page=2